RADNOSTIX, INC. (INIS) Stock Price

RADNOSTIX, INC. Price

OTC·CLOSED
0.06USD+0.0012 (+1.98 %)
Market closed

Revenue has compounded at 5.8% per year over the past 19 years to 13.07 M USD. RADNOSTIX, INC.'s net margin stands at -6.9%, up from -9.3% several years earlier. The stock trades about 22% above its 52-week low.

RADNOSTIX, INC. stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of RADNOSTIX, INC. over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how RADNOSTIX, INC. stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing RADNOSTIX, INC.'s price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

RADNOSTIX, INC. Stock Price History
DateRADNOSTIX, INC. Price
7/29/20260.06 USD
7/28/20260.06 USD
7/27/20260.07 USD
7/23/20260.06 USD
7/22/20260.07 USD
7/21/20260.07 USD
7/20/20260.07 USD
7/17/20260.07 USD
7/16/20260.07 USD
7/15/20260.07 USD
7/14/20260.07 USD
7/13/20260.06 USD
7/10/20260.07 USD
7/9/20260.07 USD
7/8/20260.07 USD
7/7/20260.06 USD
7/6/20260.07 USD
7/2/20260.07 USD
7/1/20260.08 USD
6/30/20260.07 USD
6/29/20260.07 USD
6/26/20260.07 USD
6/25/20260.07 USD
6/24/20260.08 USD
6/23/20260.08 USD
6/22/20260.07 USD
6/18/20260.07 USD
6/17/20260.07 USD
6/16/20260.07 USD
6/15/20260.07 USD
6/12/20260.07 USD
6/11/20260.08 USD
6/10/20260.08 USD
6/9/20260.07 USD
6/8/20260.07 USD
6/5/20260.07 USD
6/4/20260.08 USD
6/3/20260.07 USD
6/2/20260.08 USD
6/1/20260.07 USD
5/29/20260.08 USD
5/28/20260.08 USD
5/27/20260.08 USD
5/26/20260.07 USD
5/22/20260.07 USD
5/21/20260.08 USD
5/20/20260.08 USD
5/19/20260.08 USD
5/18/20260.09 USD
5/15/20260.09 USD
5/14/20260.09 USD
5/13/20260.08 USD
5/12/20260.08 USD
5/11/20260.08 USD
5/8/20260.09 USD
5/7/20260.09 USD
5/6/20260.08 USD
5/5/20260.08 USD
5/4/20260.08 USD
5/3/20260.08 USD
5/1/20260.08 USD
4/30/20260.07 USD
4/29/20260.07 USD
4/28/20260.07 USD
4/27/20260.08 USD
4/24/20260.08 USD
4/23/20260.08 USD
4/22/20260.08 USD
4/21/20260.08 USD
4/20/20260.07 USD
4/17/20260.08 USD
4/16/20260.08 USD
4/15/20260.08 USD
4/14/20260.08 USD
4/13/20260.08 USD
4/10/20260.09 USD
4/9/20260.08 USD
4/8/20260.09 USD
4/7/20260.08 USD
4/6/20260.08 USD
4/2/20260.08 USD
4/1/20260.08 USD
3/31/20260.08 USD
3/30/20260.07 USD
3/27/20260.08 USD
3/26/20260.07 USD
3/25/20260.09 USD
3/24/20260.09 USD
3/23/20260.09 USD
3/20/20260.09 USD
3/19/20260.09 USD
3/18/20260.08 USD
3/17/20260.08 USD
3/16/20260.07 USD
3/13/20260.09 USD
3/12/20260.06 USD
3/11/20260.07 USD
3/10/20260.07 USD
3/9/20260.09 USD
3/6/20260.09 USD
3/5/20260.08 USD
3/4/20260.07 USD
3/3/20260.09 USD
3/2/20260.09 USD
2/27/20260.09 USD
2/26/20260.09 USD
2/25/20260.09 USD
2/24/20260.08 USD
2/23/20260.08 USD
2/20/20260.09 USD
2/19/20260.09 USD
2/18/20260.09 USD
2/17/20260.08 USD
2/13/20260.09 USD
2/12/20260.07 USD
2/11/20260.10 USD
2/10/20260.08 USD
2/9/20260.08 USD
2/6/20260.09 USD
2/5/20260.07 USD
2/4/20260.07 USD
2/3/20260.08 USD
2/2/20260.07 USD
1/30/20260.07 USD
1/29/20260.07 USD
1/28/20260.07 USD
1/27/20260.07 USD
1/26/20260.07 USD
1/23/20260.07 USD
1/22/20260.07 USD
1/21/20260.07 USD
1/20/20260.07 USD
1/16/20260.07 USD
1/15/20260.07 USD
1/14/20260.07 USD
1/13/20260.07 USD
1/12/20260.07 USD
1/9/20260.07 USD
1/8/20260.07 USD
1/7/20260.06 USD
1/6/20260.06 USD
1/5/20260.06 USD
1/2/20260.06 USD
12/31/20250.06 USD
12/30/20250.06 USD
12/29/20250.06 USD
12/26/20250.06 USD
12/24/20250.06 USD
12/23/20250.06 USD
12/22/20250.07 USD
12/19/20250.06 USD
12/18/20250.06 USD
12/17/20250.07 USD
12/16/20250.07 USD
12/15/20250.07 USD
12/12/20250.06 USD
12/11/20250.07 USD
12/10/20250.06 USD
12/9/20250.07 USD
12/8/20250.07 USD
12/5/20250.07 USD
12/4/20250.06 USD
12/3/20250.07 USD
12/2/20250.06 USD
12/1/20250.06 USD
11/28/20250.06 USD
11/26/20250.06 USD
11/25/20250.07 USD
11/24/20250.07 USD
11/21/20250.06 USD
11/20/20250.06 USD
11/19/20250.06 USD
11/18/20250.06 USD
11/17/20250.07 USD
11/14/20250.07 USD
11/13/20250.08 USD
11/12/20250.08 USD
11/11/20250.09 USD
11/10/20250.09 USD
11/7/20250.09 USD
11/6/20250.09 USD
11/5/20250.11 USD
11/4/20250.09 USD
11/3/20250.11 USD
10/31/20250.10 USD
10/30/20250.09 USD
10/29/20250.07 USD
10/28/20250.06 USD
10/27/20250.06 USD
10/24/20250.05 USD
10/23/20250.06 USD
10/22/20250.06 USD
10/21/20250.05 USD
10/20/20250.06 USD
10/17/20250.06 USD
10/16/20250.05 USD
10/15/20250.06 USD
10/14/20250.06 USD
10/13/20250.06 USD
10/10/20250.05 USD
10/9/20250.06 USD
10/8/20250.06 USD
10/7/20250.06 USD
10/6/20250.06 USD
10/3/20250.06 USD
10/2/20250.06 USD
10/1/20250.06 USD
9/30/20250.06 USD
9/29/20250.06 USD
9/26/20250.06 USD
9/25/20250.06 USD
9/24/20250.06 USD
9/23/20250.06 USD
9/22/20250.06 USD
9/19/20250.06 USD
9/18/20250.06 USD
9/17/20250.06 USD
9/16/20250.06 USD
9/15/20250.06 USD
9/12/20250.07 USD
9/11/20250.06 USD
9/10/20250.06 USD
9/9/20250.07 USD
9/8/20250.07 USD
9/5/20250.07 USD
9/4/20250.07 USD
9/3/20250.08 USD
9/2/20250.08 USD
8/29/20250.08 USD
8/28/20250.08 USD
8/27/20250.09 USD
8/26/20250.09 USD
8/25/20250.09 USD
8/22/20250.09 USD
8/21/20250.09 USD
8/20/20250.09 USD
8/19/20250.09 USD
8/18/20250.09 USD
8/15/20250.09 USD
8/14/20250.09 USD
8/13/20250.10 USD
8/12/20250.11 USD
8/11/20250.11 USD
8/8/20250.11 USD
8/7/20250.10 USD
8/6/20250.11 USD
8/5/20250.10 USD
8/4/20250.10 USD
Access this data via the Eulerpool API
Get Free API Key

RADNOSTIX, INC. Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
10.37 M USD
-290,064.00 USD
-844,576.00 USD
Jan 1, 2019
8.96 M USD
-558,297.00 USD
-1.52 M USD
Jan 1, 2020
9.36 M USD
3.22 M USD
2.20 M USD
Jan 1, 2021
9.66 M USD
-240,792.00 USD
-902,347.00 USD
Jan 1, 2022
11.18 M USD
907,679.00 USD
303,238.00 USD
Jan 1, 2023
12.27 M USD
-616,126.00 USD
-869,016.00 USD
Jan 1, 2024
13.90 M USD
214,867.00 USD
8,574.00 USD
Jan 1, 2025
13.07 M USD
-956,187.00 USD
-908,002.00 USD

RADNOSTIX, INC. Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 1, 2026, 5:19 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
6.009.007.006.007.007.006.007.0010.008.009.009.0011.0012.0013.0013.00
–50.00-22.22-14.2916.67–-14.2916.6742.86-20.0012.50–22.229.098.33–
33.3333.3342.8633.3328.5728.5733.3342.8640.0050.0055.5655.5654.5558.3361.5453.85
2.003.003.002.002.002.002.003.004.004.005.005.006.007.008.007.00
–––-2.00–-1.00-1.00-2.00––3.00–––––
–––-33.33–-14.29-16.67-28.57––33.33–––––
–––-2.00-1.00-1.00-1.00-3.00–-1.002.00–––––
––––-50.00––200.00––-300.00–––––
8.118.118.118.118.118.118.118.118.118.118.118.118.118.118.118.11
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales RADNOSTIX, INC. generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue RADNOSTIX, INC. retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare RADNOSTIX, INC.'s gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares RADNOSTIX, INC. has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against RADNOSTIX, INC.'s historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

RADNOSTIX, INC. stock margins

The RADNOSTIX, INC. margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RADNOSTIX, INC.. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RADNOSTIX, INC..

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
45.23 %
-2.80 %
-8.15 %
Jan 1, 2019
52.10 %
-6.23 %
-17.01 %
Jan 1, 2020
58.30 %
34.40 %
23.52 %
Jan 1, 2021
59.39 %
-2.49 %
-9.34 %
Jan 1, 2022
56.25 %
8.12 %
2.71 %
Jan 1, 2023
60.15 %
-5.02 %
-7.08 %
Jan 1, 2024
62.22 %
1.55 %
0.06 %
Jan 1, 2025
58.93 %
-7.32 %
-6.95 %

RADNOSTIX, INC. Stock Revenue, EBIT, Earnings per Share

The RADNOSTIX, INC. earnings per share therefore indicates how much revenue RADNOSTIX, INC. has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

RADNOSTIX, INC. business model & stock analysis

International Isotopes Inc. is a company specializing in the production and sale of radioactive isotopes, chemicals, and materials. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho. Its main goal is to meet the demand for high-quality radioactive isotopes for medical and industrial use. Over the years, the company has diversified its business and now offers a wide variety of products and services. It produces and sells a range of radioactive isotopes, chemicals, and materials, including medical and industrial radioisotopes, radiation protection products, and nuclear fuels. Additionally, International Isotopes manufactures and distributes biofuels derived from biomass such as corn and cattle. These biofuels serve as an environmentally friendly alternative to conventional fossil fuels. The company also offers a program for the disposal of radioactive waste, providing services to remove nuclear materials from medical, industrial, and scientific facilities. In terms of medical radioisotopes, International Isotopes produces a wide range of isotopes, including technetium-99, a crucial substance for medical imaging diagnostics. The company also supplies specialized radioactive materials used in cancer diagnostics and radiation therapy. Industrial radioisotopes are another important product line for the company, including materials used in medical radiation therapy, as well as radiation sources used in measurement and control technology. International Isotopes also manufactures various products used in radiation protection, such as protective clothing, shielding materials, and radiation containment vessels. Furthermore, the company is involved in the supply of nuclear fuels for various applications, ranging from military facilities to civilian nuclear power plants. In summary, International Isotopes offers a wide range of products and services, specializing in the important field of radioactive isotopes and providing solutions in the areas of medicine, industry, research, and the environment.

RADNOSTIX, INC. SWOT Analysis

Strengths

  • Extensive experience and expertise in the field of isotopes and radiation products
  • Strong financial position and stable revenue streams
  • Diverse product portfolio catering to various industries and applications
  • Strong relationships with suppliers and customers

Weaknesses

  • Relatively small market share compared to larger competitors
  • Dependence on regulatory approvals for product development and market entry
  • Limited brand recognition and customer loyalty
  • Limited resources for aggressive marketing and advertising campaigns

Opportunities

  • Growing demand for medical isotopes in diagnostic and therapeutic applications
  • Increasing adoption of radiation-based technologies in various industries
  • Emerging markets in developing countries provide expansion opportunities
  • Potential partnerships and collaborations with research institutions and healthcare organizations

Threats

  • Intense competition from larger and well-established players in the industry
  • Stringent regulations and compliance requirements for radioactive materials
  • Volatility in raw material prices affecting production costs
  • Technological advancements potentially making current products obsolete

RADNOSTIX, INC. Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

RADNOSTIX, INC. Employees
Details
Date
RADNOSTIX, INC. Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

RADNOSTIX, INC. Segments

RADNOSTIX, INC. Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Theranostics Products
Segment Total
Consolidated Total
Radiochemical Products
Nuclear Medicine Products
Nuclear Medicine Standards
Cobalt Products
Radiological Services
Transportation
Medical Device Products
Fluorine Products
Corporate Allocation
Details
Date
Theranostics Products
Segment Total
Consolidated Total
Radiochemical Products
Nuclear Medicine Products
Nuclear Medicine Standards
Cobalt Products
Radiological Services
Transportation
Medical Device Products
Fluorine Products
Corporate Allocation
Jan 1, 2014
0.00 USD
7.54 M USD
7.54 M USD
1.74 M USD
0.00 USD
3.27 M USD
1.79 M USD
621,431.00 USD
113,775.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
2.26 M USD
3.79 M USD
0.00 USD
2.04 M USD
2.27 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
2.85 M USD
3.93 M USD
0.00 USD
846,404.00 USD
1.17 M USD
0.00 USD
0.00 USD
160,500.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
4.07 M USD
3.67 M USD
0.00 USD
1.23 M USD
216,139.00 USD
0.00 USD
0.00 USD
178,350.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
4.28 M USD
3.84 M USD
0.00 USD
1.35 M USD
160,159.00 USD
0.00 USD
0.00 USD
29,775.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
6.05 M USD
3.98 M USD
0.00 USD
1.16 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
6.84 M USD
0.00 USD
0.00 USD
0.00 USD
4.39 M USD
0.00 USD
1.04 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
3.52 M USD
0.00 USD
2.37 M USD
0.00 USD
0.00 USD
8,657.00 USD
0.00 USD
0.00 USD

RADNOSTIX, INC. Revenue by Segment (2/2)

  • Max

Theranostics Products
Details
Date
Theranostics Products
Jan 1, 2014
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
8.01 M USD

RADNOSTIX, INC. Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Other Countries
Outside U.S
Details
Date
United States
Other Countries
Outside U.S
Jan 1, 2018
8.26 M USD
0.00 USD
2.11 M USD
Jan 1, 2019
7.26 M USD
0.00 USD
1.69 M USD
Jan 1, 2020
8.08 M USD
0.00 USD
1.28 M USD
Jan 1, 2021
8.20 M USD
0.00 USD
1.46 M USD
Jan 1, 2022
9.65 M USD
0.00 USD
1.53 M USD
Jan 1, 2023
10.02 M USD
2.24 M USD
0.00 USD

RADNOSTIX, INC. Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

RADNOSTIX, INC. historical P/E ratio, EBIT multiple, and P/S ratio

RADNOSTIX, INC. annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

RADNOSTIX, INC. shares outstanding

The number of shares of RADNOSTIX, INC. was 528.21 M in 2025. This indicates how many shares RADNOSTIX, INC. is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
528.21 M Stocks
Jan 1, 2019
528.21 M Stocks
Jan 1, 2020
528.21 M Stocks
Jan 1, 2021
528.21 M Stocks
Jan 1, 2022
528.21 M Stocks
Jan 1, 2023
528.21 M Stocks
Jan 1, 2024
528.21 M Stocks
Jan 1, 2025
528.21 M Stocks
Price targets and forecasts for RADNOSTIX, INC. are not yet available.

RADNOSTIX, INC. shareholder structure

% Name
19.44787%
McCormack (John M)
McCormack (John M)
10.56270%
Grosso (Christopher G.)
Grosso (Christopher G.)
2.42076%
Laflin (Steve T)
Laflin (Steve T)
1.70898%
Bagerdjian (Shahe)
Bagerdjian (Shahe)
0.20997%
Cox (W Matthew)
Cox (W Matthew)
0.14199%
Atcher (Robert)
Atcher (Robert)

RADNOSTIX, INC. Beneficial Ownership Filings (SEC 13D/G)

Free Float
20.2%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
42.96%
Kennerman Associates, Inc. d/b/a Kershner Grosso & Co.
Kennerman Associates, Inc. d/b/a Kershner Grosso & Co.
SEC ↗
42.40%
Kennerman Associates, Inc.
Kennerman Associates, Inc.
SEC ↗
11.76%
Christopher Grosso
Christopher Grosso
SEC ↗
10.00%
DKR MANAGEMENT COMPANY, INC.
DKR MANAGEMENT COMPANY, INC.
SEC ↗
6.00%
James J. Keane
James J. Keane
SEC ↗
5.30%
Marie C. Keane
Marie C. Keane
SEC ↗
3.10%
Fort Worth, TX 76102
Fort Worth, TX 76102
SEC ↗
1.80%
Thomas Kershner
Thomas Kershner
SEC ↗
0.11%
Debello Investors LLC
Debello Investors LLC
SEC ↗

RADNOSTIX, INC. Executives and Management Board

SB

Mr. Shahe Bagerdjian

(41)

President, Chief Executive Officer, Director · since 2023

Compensation429,702.00 USD
SL

Mr. Steve Laflin

(68)

Director · since 2001

Compensation378,625.00 USD
WC

Mr. W. Matthew Cox

(41)

Chief Financial Officer, Secretary

Compensation148,654.00 USD
RA

Dr. Robert Atcher

(73)

Independent Director

Compensation108,304.00 USD
CG

Mr. Christopher Grosso

(57)

Independent Chairman of the Board

Compensation41,980.00 USD

Frequently asked questions about RADNOSTIX, INC.

International Isotopes Inc operates as a provider of nuclear medicine products and services. The company offers a wide range of radioisotopes, including those used in medical imaging, diagnosis, and therapy. Its business model revolves around producing and supplying high-quality radiopharmaceuticals, radiological devices, and related services to the global healthcare industry. International Isotopes Inc also provides consulting services and specialized software to assist medical professionals in utilizing their products effectively. With a focus on continuous innovation and quality assurance, the company serves as a reliable partner in the advancement of nuclear medicine technologies and treatments.

All fundamentals and in-depth analysis of RADNOSTIX, INC.

Our stock analysis for RADNOSTIX, INC. stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RADNOSTIX, INC.. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

RADNOSTIX, INC. Stock
RADNOSTIX, INC. Revenue→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Net Income→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. P/E→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. P/S→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. EBIT→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Dividend→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Directors Dealings→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Stocks→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Market capitalization→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Debt→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Liabilities→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Equity→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. AAQS→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Employees→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. ROE→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. ROA→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. ROCE→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. News→
RADNOSTIX, INC. Stock
RADNOSTIX, INC. Analyst Price Targets→

Health Stocks

Raffles Medical GroupRadNetRaily Aesthetic Medicine International HoldingsRadiopharm TheranosticsRain Enhancement Technologies HoldcoRadiant InnovationRainbow Children's MedicareRacura OncologyRainmed MedicalR&G PharmaStudies CoRajthanee Hospital PCLQurient CoAll Stocks A–Z →